Fee-For-Service Screening
Dear
Customer,
In
a response to the rapidly increasing popularity of our screening
services we have developed a new client focused process. The first
step of this process is to make sure that from the very beginning of
the project we align your screening needs with the various service
packages that we offer.
This
insures that we deliver on your screening objectives in a fast,
reliable and focused manner. In order to achieve this, we have
created this on line form to help us better understand your screening
needs and objectives straight from the start.
So please take
a few minutes to register and fill this form detailing your
screening requirements! Once you have sent this form on line, you
will receive an email confirmation of your request. A member of the
Solvo Business Development team will then get in touch with you
shortly to discuss the details of the project.
Thank you for
using our form!
Fee-For-Service
Screening Request Form
We
recommend this type of service for customers who would like to test a
limited number of compounds (typically <20) more thoroughly by
directly utilizing Solvo Biotechnology in vitro testing experience.
Typically these assays are performed on compounds in lead
optimization or at a later stage, in drug development (preclinical or
clinical). We are ready to handle larger compound sets too, however,
for large scale screening we suggest to establish these assays in
house. We have great expertise in assisting our customers in adapting
these assays for in house applications.
ABC
Transporter interaction testing might help to understand the
mechanism behind the ambiguous ADME/Tox profile of certain drug
candidates.
In
our lab, we can perform all the ABC transporter measurements listed
on our Membrane
Preparations
page:
A.
ABC (efflux) Transporter Assays
1. ATPase Assays [ATPase activation + inhibition]
|
Transporter
|
Membrane
used
|
Reference
substrate
|
Positive
control
activation
/ inhibition
|
Short description
|
|
MDR1 / PgP (ABCB1)
|
SB-MDR1-Sf9-ATPase
|
Verapamil
|
Digoxin / Cyclosporine
A
|
Short Description |
|
rat Mdr1b
|
SB-ratMdr1b-Sf9-ATPase
|
Verapamil
|
Quinidine / Cyclosporine A
|
Short Description |
|
rat Mdr1a
|
Under development |
|
MRP1 (ABCC1)
|
SB-MRP1-Sf9-ATPase
|
NEM-GS
|
Indomethacin / Benzbromarone
|
Short Description |
|
MRP2 (ABCC2)
|
SB-MRP2-Sf9-ATPase
|
Probenecid
|
Sulfasalazine / Benzbromarone
|
Short Description |
|
rat Mrp2
|
SB-ratMrp2-Sf9-ATPase
|
Probenecid
|
Sulfasalazine / Benzbromarone
|
Short Description |
|
MRP3 (ABCC3)
|
SB-MRP3-Sf9-ATPase
|
Benzbromarone
|
E217βG / Cyclosporine A
|
Short Description |
|
BCRP (ABCG2)
|
SB-BRCP-M-ATPase or SB-BCRPHAM-Sf9-ATPase
|
Sulfasalazine, Hoechst 33342,
KO143
|
Topotecan / KO143
|
Short Description |
|
BCRP / MXR – R482G1
(ABCG2-R482G)
|
SB-BCRP-R482G-Sf9-ATPase
|
Prazosin, Hoechst 33342, KO143
|
Mitoxanthron / KO143
|
Short Description |
Substrate
/ inhibitor used: test drug or test drug + posCTRL
Deliverables:
EC50, IC50
Suggested
concentration range of test drug: 137 nM – 300 µM
1
Mutant variant (not wild type)
2.
Vesicular Transport Assays
|
Transporter
|
Membrane
used
|
Reference
(reporter) substrate used
|
Positive
control
|
Short description
|
|
MRP1 (ABCC1)
|
SB-MRP1-Sf9-VT
|
3H-LTC4 or
radioactive form of test drug (TD)
|
MK571
|
Short Description |
|
MRP2 (ABCC2)
|
SB-MRP2-Sf9-VT
|
3H-E217βG
or radioactive form of TD
|
Benzbromarone
|
Short Description |
|
MRP3 (ABCC3)
|
SB-MRP3-Sf9-VT
|
3H-E217βG
or radioactive form of TD
|
Benzbromarone
|
Short Description |
|
MRP5 (ABCC5)
|
SB-MRP5-HEK293-VT
|
3H-cGMP (1 µM)
|
Benzbromarone
|
Short Description |
|
MRP6 (ABCC6)
|
Under development |
|
BCRP / MXR (ABCG2)
|
SB-BCRP-M-VT
|
3H-Estrone-3-sulfate or
radioactive form of TD
|
Methotrexate
|
Short Description |
|
BCRP / MXR (ABCG2)
|
SB-BCRP-HAM-Sf9-VT
|
3H-Estrone-3-sulfate or 3H-Methotrexate
|
Methotrexate
|
Short Description |
|
BCRP / MXR (ABCG2)
|
SB-BCRP-Sf9-VT
|
3H-Methotrexate
or radioactive form of TD
|
Estrone-3-sulfate
|
Short Description |
|
mouse BCRP
|
Under development |
|
BSEP (ABCB11)
|
SB-BSEP-Sf9-VT
|
3H-Taurocholate or
radioactive form of TD
|
Cyclosporin A
|
Short Description |
|
mouse BSEP
|
SB-mouseBSEP-Sf9-VT
|
3H-Taurocholate
|
Cyclosporine A
|
Short Description |
|
rat BSEP
|
Under development |
|
ABCA1, ABCG5/G8
|
Under development |
Deliverables:
IC50 – for interacting compounds
(Follow-up
studies are available, which provide kinetic data: Km, Ki
and Vmax)
Concentration
range of test drug: 0.41 µM
– 300 µM
3.
Dye Transport Assays
|
Transporter
|
Cell
line used
|
Dye
used
|
Positive
control
|
Short description
|
|
MDR1 / PgP (ABCB1)
|
HL60-MDR or K562-MDR
|
Calcein AM
|
Verapamil
|
Short Description |
|
MRP1 (ABCC1)
|
HL60-MRP
|
Calcein AM
|
MK571
|
Short Description |
|
MXR / BCRP (ABCG2)
|
MXR-M
|
Hoechst 33342
|
Propietary
|
Short Description |
Deliverables:
IC50
Suggested
concentration range of test drug: 0,07 µM – 150 µM
4.
Nucleotide Trapping
Available
for MDR1, MRP1, MRP2, rat Mrp2, MXR and MDR2 (MDR3). Costs are
individually based.
B.
Uptake Transporter Assays
| Transporter | Reporter substrate | Reference inhibitor | Cell type | Negative control |
OATP1B1 (SLCO1B1) | 3H-Estrone-3-Sulfate | Cerivastatin | CHO | Parental cells |
OATP1B3 (SLCO1B3) | Fluo-3 | Fluvastatin | CHO | Parental cells |
OATP2B1 (SLCO2B1) | 3H-Estrone-3-Sulfate | Fluvastatin | MDCKII | Parental cells |
rat Oatp1a1 (Slco1a1) | 3H-Estrone-3-Sulfate | Ketoconazole | CHO | Parental cells |
NTCP (SLC10A1) | 3H-Taurocholate | Taurochenodeoxycholate | CHO | Na+ free buffer |
rNtcp (Slc10a1) | 3H-Taurocholate | Taurochenodeoxycholate | CHO | Na+ free buffer |
PEPT1 (SLC15A1) | Gly-Sar | Tyr-Phe | CHO | Parental cells |
PEPT2 (SLC15A2) | Gly-Sar | Cefadroxil | CHO | Parental cells |
PEPT2 (SLC15A2) | Gly-Sar | Cefadroxil | CHO | Parental cells |
PEPT2 (SLC15A2) | Gly-Sar | Cefadroxil | CHO | Parental cells |
| OAT1 | 3H-p-Aminohippuric acid (PAH) | Benzbromarone | CHO | Parental cells |
| OCT1 | 14C-Tetraethylammonium-chloride (TEA) | Verapamil | CHO | Parental cells |
C. Monolayer Assays
Monolayer systems consist of a tight cell layer grown on a porous support to separate two fluid compartments. They are widely regarded as the most sophisticated in vitro tools for medium to high throughput modelling of important pharmacokinetic barriers, such as intestinal epithelium, blood-brain barrier etc (see Hamilton RD et al. 2007. for a recent application).
Two systems that are applied widely in monolayer studies are the human colon carcinoma cell line Caco-2 and transfectant MDCKII cells. SOLVO offers several options for both systems.
Caco2 screening services:
1. Passive permeability studies
2. Specific transporter studies
3. Drug-Drug Interaction studies
SOLVO offers a number of standard setups for the above listed studies, which differ in the amount of information derived and costs.
| √ Basic | - Studies at one concentration |
| √ Extended | - Studies at several concentrations, more controls |
| √ FDA Guidelines | - Studies according to FDA draft guidance (2006) |
These standard packages can be customized to suite your needs.
MDCKII screening services:
| Cell line | Application | Positive control | Negative control |
| MDCKII-BCRP | Direct BCRP interaction | Transport of Prazosin | Parental cell line |
| | Inhibition of prazosin transport | Ko134 | NA |
| MDCKII-mBcrp1 | Direct mBcrp1 interaction | Transport of Prazosin | Parental cell line |
| | nhibition of prazosin transport | Ko134 | NA |
MDCKII- OATP2B1/BCRP | Direct vectorial transport | Estrone-3-Sulfate transport | Parental cell line and BCRP, OATP2B1 single transfectants |
| | Inhibition of Estrone-3-Sulfate transport | Estrone and Ko134 | NA |
| MDCKII-NTCP/BSEP | Under development |
| LLC-PK1-MDR1 | Under development |
D. Other Assays
SOLVO development pipelin also includes the following elements: Vectorial assays, Physiological Barrier Models, Toxicity Microarray, Transporter chip, Transporter humanized knock-out and knock-in animals. Different new assays are under development for several other human and animal ABC efflux and uptake transporters.
General
Remarks
Screening
results are usually available within 4 to 10 weeks. The schedule
might depend on the actual workload of SOLVO’s laboratory. We
can provide a final schedule before contracting, including needed
quantity of test drugs. Performing inhibition and activation assays
is always strongly recommended.
Assays
are carried out in duplicates. Upon request of customer, assays can
be carried out in triplicates. Positive controls are also available.
We
provide a detailed report at the end of each task, including a guide
for conclusions.
PRICES ARE AVAILABLE UPON REQUEST.
Additional volume based discounts are also available!
|
|